Table 2: Huntington’s Disease.

In this table, all clinically relevant in PubMed from 2000–2018 using intracerebral transplant for Huntington’s Disease are cited. In summary, these milestone studies showed that CP cells, iPSCs, and ESCs transplantation promotes reduction of lesion size, migration and proliferation in the striatum in animal models of HD. In humans with HD, fetal tissue implantation results in improved cognitive and motor function, but the cells do not survive long term or become permanently engrafted within the striatum.

Authors	Model	Cell Type	Cell Quantity	Outcomes
Emerich et al., 2006	Primate intracerebral	CP	50,000 cells per mL	Reduction of lesion volume by 5-fold
Mu et al., 2014	Rodent Intrastriatal	iPSCs	1,000,000 cells	Migration of iPSCs to striatum and differentiation into glial cells
Borlongan et al., 2007	Rodent Intracerebral	CP	50,000 cells per mL	Attraction of glial cells and proliferation in the striatum
Bachoud-Levi et al., 2000	Human intrastriatal	Fetal striatal tissue	Not Specified	Improved cognitive and motor function in daily activities
Keene et al., 2007	Human intracerebral	Fetal tissue	Not Specified	Grafts exhibited limited to no HD characteristics
Bachoud-Levi et al., 2006	Human intracerebral	Fetal Neuronal Tissue	Not Specified	Grafts showed unhealthy morphology and no survival in the caudate region
Jiang et al., 2011	Rodent intrastriatal	Embryonic cells	130,000 cells/μl	Greater levels of striatal-like neurons in graft sites

HD – Huntington’s Disease; ESC – embryonic stem cells; iPSC – induced pluripotent stem cells; CP – choroid plexus